menu

Medical Program: Reviewing First-Line Systemic Therapies for Metastatic Non-Small Cell Lung Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reviewing First-Line Systemic Therapies for Metastatic Non-Small Cell Lung Cancer

close
Reviewing First-Line Systemic Therapies for Metastatic Non-Small Cell Lung Cancer
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Sponsored by

  • Overview

    To help us treat the disease representing the most common cause of cancer mortality worldwide—with more than half of patients presenting with stage IV disease at diagnosis—Dr. Jennifer Caudle speaks with Dr. Stephen Liu, who reviews the various recommended first-line systemic therapies for non-small cell lung cancer, the rationales behind single agents versus combinations, and strategies to guide patients through their treatment course. 

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    To help us treat the disease representing the most common cause of cancer mortality worldwide—with more than half of patients presenting with stage IV disease at diagnosis—Dr. Jennifer Caudle speaks with Dr. Stephen Liu, who reviews the various recommended first-line systemic therapies for non-small cell lung cancer, the rationales behind single agents versus combinations, and strategies to guide patients through their treatment course. 

Facebook Comments

Programs 5/16/21